Deferitrin

TargetMol
Product Code: TAR-T19692
Supplier: TargetMol
CodeSizePrice
TAR-T19692-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-1mL1 mL * 10 mM (in DMSO)£293.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-5mg5mg£313.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-10mg10mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-25mg25mg£670.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-50mg50mg£914.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-100mg100mg£1,211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T19692-500mg500mg£2,344.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Deferitrin is an iron chelator. It potentially for the treatment of thalassemia and iron overload.
CAS:
239101-33-8
Formula:
C11H11NO4S
Molecular Weight:
253.27
Purity:
0.9978
SMILES:
C[C@@]1(CSC(=N1)c1ccc(O)cc1O)C(O)=O

References

1. Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011 Apr;24(2):239-58. Central PMCID: PMC3329216. 2. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008 Jul 10;51(13):3913-23. 3. Barton JC. Drug evaluation: Deferitrin for iron overload disorders. IDrugs. 2007 Jul;10(7):480-90. PubMed PMID: 17642018. 4. Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs. 2007 Apr;10(4):270-81. Review.